Natera, Inc. NTRA
13 trading plans running, 106 Form 144 notices for $322.1M
10-Q, 10-K and Form 144What NTRA's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Dec 10, 2025 to Sep 12, 2028. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.
| Insider | What | Date | Reported in | ||
|---|---|---|---|---|---|
| Daniel Rabinowitz chief legal officer and secretary |
Adopted 10b5-1 plan | Sep 14, 2026 | 10-Q Nov 5, 2026 | ||
What the company wroteOn September 14, 2026, Daniel Rabinowitz, our chief legal officer and secretary, adopted a Rule 10b5-1 Trading Plan that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Rabinowitz’s Rule 10b5-1 Trading Plan provides for the potential sale of up to 60,000 shares of our common stock pursuant to the terms of the plan between January 2, 2027 and December 31, 2028. | |||||
| John Fesko chief business officer |
Adopted 10b5-1 plan | Sep 14, 2026 | 10-Q Nov 5, 2026 | ||
What the company wroteOn September 14, 2026, John Fesko, our chief business officer, adopted a Rule 10b5-1 Trading Plan that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Fesko’s Rule 10b5-1 Trading Plan provides for the potential sale of up to 90,000 shares of our common stock pursuant to the terms of the plan between December 14, 2026 and December 31, 2027. | |||||
| Matthew Rabinowitz executive chairman |
Adopted 10b5-1 plan | Sep 14, 2026 | 10-Q Nov 5, 2026 | ||
What the company wroteOn September 14, 2026, Matthew Rabinowitz, our executive chairman, adopted a trading arrangement for the sale of shares of our common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Dr. Rabinowitz’s Rule 10b5-1 Trading Plan provides for the potential sale of up to 200,000 shares of our common stock pursuant to the terms of the plan between January 19, 2027 and July 19, 2027. | |||||
| Matthew Rabinowitz executive chairman |
Adopted 10b5-1 plan | Jun 12, 2026 | 10-Q Aug 7, 2026 | ||
What the company wroteOn June 12, 2026, Matthew Rabinowitz, our executive chairman, adopted a trading arrangement for the sale of shares of our common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Dr. Rabinowitz’ Rule 10b5-1 Trading Plan provides for the potential sale of up to 200,000 shares of our common stock pursuant to the terms of the plan between September 11, 2026 and February 19, 2027. | |||||
| Matthew Rabinowitz executive chairman |
Adopted 10b5-1 plan | Mar 13, 2026 | 10-Q May 8, 2026 | ||
What the company wroteOn March 13, 2026, Matthew Rabinowitz, our executive chairman, adopted a trading arrangement for the sale of shares of our common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Dr. Rabinowitz’ Rule 10b5-1 Trading Plan provides for the potential sale of up to 100,000 shares of our common stock pursuant to the terms of the plan between June 12, 2026 and December 17, 2026. | |||||
| Steve Chapman chief executive officer |
Adopted 10b5-1 plan | Mar 5, 2026 | 10-Q May 8, 2026 | ||
What the company wroteOn March 5, 2026, Steve Chapman, our chief executive officer, modified a Rule 10b5-1 Trading Plan to provide for the potential sale of 180,643 shares of our common stock pursuant to the terms of the plan between June 4, 2026 and March 31, 2028. A significant portion of the shares subject to the plan would not be sold unless the Company achieves specified performance targets. | |||||
| Jonathan Sheena member of our board of directors |
Adopted 10b5-1 plan | Dec 12, 2025 | 10-K Feb 27, 2026 | ||
What the company wroteOn December 12, 2025, Jonathan Sheena, a member of our board of directors, adopted a Rule 10b5-1 Trading Plan that provides for the sale of 59,000 shares of our common stock pursuant to the terms of the plan between May 8, 2026 and June 21, 2027. | |||||
| Rowan Chapman a member of our board of directors |
Adopted 10b5-1 plan | Dec 12, 2025 | 10-K Feb 27, 2026 | ||
What the company wroteOn December 12, 2025, Rowan Chapman, a member of our board of directors, adopted a Rule 10b5-1 Trading Plan that provides for the sale of 3,221 shares of our common stock pursuant to the terms of the plan between March 13, 2026 and December 1, 2026. | |||||
| Matthew Rabinowitz our co-founder and executive chairman |
Adopted 10b5-1 plan | Dec 11, 2025 | 10-K Feb 27, 2026 | ||
What the company wroteOn December 11, 2025, Matthew Rabinowitz, our co-founder and executive chairman, adopted a Rule 10b5-1 Trading Plan that provides for the sale of 200,000 shares of our common stock pursuant to the terms of the plan between March 12, 2026 and August 31, 2026. | |||||
| Herm Rosenman a member of our board of directors |
Adopted 10b5-1 plan | Dec 10, 2025 | 10-K Feb 27, 2026 | ||
What the company wroteOn December 10, 2025, Herm Rosenman, a member of our board of directors, adopted a Rule 10b5-1 Trading Plan that provides for the exercise of 16,530 stock options and sale of underlying shares of our common stock pursuant to the terms of the plan between March 11, 2026 and December 10, 2026. | |||||
| Daniel Rabinowitz our chief legal officer |
Adopted 10b5-1 plan | Dec 5, 2025 | 10-K Feb 27, 2026 | ||
What the company wroteInsider Trading Arrangements and Policies On December 5, 2025, Daniel Rabinowitz, our chief legal officer, adopted a trading arrangement for the sale of shares of the Company’s common stock intended to satisfy the affirmative defense of Rule 10b5-1(c) (a “Rule 10b5-1 Trading Plan”) that provides for the sale of 61,600 shares of our common stock and the exercise of 5,598 stock options and sale of underlying shares of our common stock, pursuant to the terms of the plan between March 6, 2026 and December 5, 2027. | |||||
| Mike Brophy chief financial officer |
Adopted 10b5-1 plan | Sep 10, 2025 | 10-Q Nov 7, 2025 | ||
What the company wroteOn September 10, 2025, Mike Brophy, our chief financial officer, amended a Rule 10b5-1 Trading Plan to provide for the potential sale of up to 128,846 shares of our common stock pursuant to the terms of the plan between February 2, 2026 and February 8, 2028. A significant portion of the shares subject to the plan would not be sold unless the Company achieves specified performance targets. | |||||
| Roy Baynes a member of the Company’s board of directors |
Adopted 10b5-1 plan | Aug 20, 2025 | 10-Q Nov 7, 2025 | ||
What the company wroteOn August 20, 2025, Roy Baynes, a member of the Company’s board of directors, adopted a trading arrangement for the sale of securities of the Company’s common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Baynes’ Rule 10b5-1 Trading Plan provides for the exercise of 12,780 stock options and sale of underlying shares of common stock pursuant to the terms of the plan, between November 19, 2025 and August 31, 2027. | |||||
| Mike Brophy chief financial officer |
Adopted 10b5-1 plan | Jun 10, 2025 | 10-Q Aug 8, 2025 | ||
What the company wroteOn June 10, 2025, Mike Brophy, our chief financial officer, adopted a trading arrangement for the sale of securities of the Company’s common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Brophy’s Rule 10b5-1 Trading Plan provides for the sale of up to 122,596 shares of common stock pursuant to the terms of the plan between February 2, 2026 and February 8, 2028. | |||||
| Gail Marcus member of our board of directors |
Adopted 10b5-1 plan | Dec 11, 2024 | 10-K Feb 28, 2025 | ||
What the company wrote On December 11, 2024, Gail Marcus, a member of our board of directors, adopted a Rule 10b5-1 Trading Plan that provides for the sale of 6,618 shares of our common stock and the exercise of 16,299 stock options and sale of underlying shares of our common stock, pursuant to the terms of the plan between March 12, 2025 and December 31, 2025. | |||||
| Jonathan Sheena co-founder and a member of our board of directors |
Adopted 10b5-1 plan | Dec 11, 2024 | 10-K Feb 28, 2025 | ||
What the company wrote On December 11, 2024, Jonathan Sheena, our co-founder and a member of our board of directors, adopted a Rule 10b5-1 Trading Plan that provides for the sale of 49,911 shares of our common stock pursuant to the terms of the plan between April 4, 2025 and April 29, 2026. | |||||
| Matthew Rabinowitz co-founder and executive chairman |
Adopted 10b5-1 plan | Dec 3, 2024 | 10-K Feb 28, 2025 | ||
What the company wrote On December 3, 2024, Matthew Rabinowitz, adopted a Rule 10b5-1 Trading Plan that provides for the sale of 130,000 shares of our common stock pursuant to the terms of the plan between March 4, 2025 and August 23, 2025. | |||||
| Solomon Moshkevich president |
Adopted 10b5-1 plan | Nov 26, 2024 | 10-K Feb 28, 2025 | ||
What the company wrote | |||||
| Roy Baynes member of our Board of Directors |
Adopted 10b5-1 plan | Aug 12, 2024 | 10-Q Nov 12, 2024 | ||
What the company wroteOn August 12, 2024 , Roy Baynes , a member of our Board of Directors , adopted a trading arrangement for the sale of shares of our common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Baynes Rule 10b5-1 Trading Plan provides for the exercise of 37,230 stock options and sale of underlying shares of our common stock pursuant to the terms of the plan between November 11, 2024 and December 31, 2025. | |||||
| Daniel Rabinowitz chief legal officer |
Adopted 10b5-1 plan | Jun 14, 2024 | 10-Q Nov 12, 2024 | ||
What the company wroteOn June 14, 2024 , Daniel Rabinowitz , our chief legal officer , adopted a trading arrangement for the sale of shares of our common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Rabinowitz’s Rule 10b5-1 Trading Plan provides for the sale of 26,131 shares of our common stock pursuant to the terms of the plan between December 15, 2024 and August 15, 2026. | |||||
| Mike Brophy chief financial officer |
Adopted 10b5-1 plan | Jun 14, 2024 | 10-Q Nov 12, 2024 | ||
What the company wroteOn June 14, 2024 , Mike Brophy , our chief financial officer , adopted a trading arrangement for the sale of shares of our common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Brophy’s Rule 10b5-1 Trading Plan provides for the potential sale of up to 109,293 shares of our common stock pursuant to the terms of the plan between February 2, 2025 and February 1, 2026. | |||||
| Jonathan Sheena co-founder and a member of our board of directors |
Adopted 10b5-1 plan | Dec 12, 2023 | 10-K Feb 29, 2024 | ||
| Steve Chapman chief executive officer |
Ended other arrangement | Dec 8, 2023 | 10-K Feb 29, 2024 | ||
| Steve Chapman chief executive officer |
Ended 10b5-1 plan | Oct 11, 2023 | 10-Q Nov 9, 2023 | ||
What the company wroteOn October 11, 2023, Steve Chapman, our chief executive officer, terminated a trading arrangement for the sale of the Company's common stock. Such trading arrangement was not intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c), but complied with the then-applicable requirements of Rule 10b5-1(c) when adopted in September 2021. Such trading arrangement provided for the sale of up to 50,910 shares between April 1, 2022 and May 1, 2022. | |||||
| Herm Rosenman a member of the Company’s board of directors |
Adopted 10b5-1 plan | May 19, 2023 | 10-Q Aug 4, 2023 | ||
What the company wroteOn May 19, 2023, Herm Rosenman, a member of the Company’s board of directors, adopted a trading arrangement for the sale of securities of the Company’s common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Rosenman’s Rule 10b5-1 Trading Plan provides for the exercise of 93,901 stock options and sale of underlying shares of common stock pursuant to the terms of the plan, between August 18, 2023 and February 23, 2024. | |||||
| Daniel Rabinowitz chief legal officer and secretary |
Adopted plan | – | 10-Q May 9, 2025 | ||
What the company wroteOn March 14, 2025, Daniel Rabinowitz, our chief legal officer and secretary, amended a Rule 10b5-1 Trading Plan to provide for the sale of 19,908 shares of our common stock pursuant to the terms of the plan between June 13, 2025 and August 15, 2026. | |||||
| Matthew Rabinowitz co-founder and executive chairman |
Adopted 10b5-1 plan | – | 10-Q May 9, 2025 | ||
What the company wroteOn March 14, 2025, Matthew Rabinowitz, our co-founder and executive chairman, adopted a trading arrangement for the sale of securities of the Company’s common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Dr. Rabinowitz’s Rule 10b5-1 Trading Plan provides for the sale of 80,000 shares of common stock pursuant to the terms of the plan between June 13, 2025 and December 13, 2025. | |||||
| Roy Baynes member of the Company's board of directors |
Adopted 10b5-1 plan | – | 10-Q Nov 5, 2026 | ||
What the company wroteOn September 14 2026, Roy Baynes, a member of the Company's board of directors, adopted a Rule 10b5-1 Trading Plan that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Baynes’ Rule 10b5-1 Trading Plan provides for the exercise of up to 6,869 stock options and sale of underlying shares of common stock pursuant to the terms of the plan, between December 14, 2026 and December 15, 2027. | |||||
| Steve Chapman chief executive officer |
Adopted plan | – | 10-K Feb 28, 2025 | ||
What the company wrote On November 26, 2024, Solomon Moshkevich, our president, clinical diagnostics, adopted a Rule 10b5-1 Trading Plan that provides for the sale of up to 66,000 shares of our common stock pursuant to the terms of the plan between March 4, 2025 and November 30, 2026. On December 2, 2024, Steve Chapman, our chief executive officer, amended a Rule 10b5-1 Trading Plan to provide for the potential sale of up to 395,452 shares of our common stock and the exercise of 156,825 stock options and sale of underlying shares of our common stock, pursuant to the terms of the plan between March 5, 2025 and November 30, 2026. A significant portion of the shares subject to the plan would not be sold unless the Company achieves specified performance targets. | |||||
Show the other 21 plans
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 10, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Nov 3, 2026 | MICHAEL BROPHY Officer |
470 | $178K |
| Nov 2, 2026 | JOHN FESKO OFFICER |
291 | $121K |
| Nov 2, 2026 | SOLOMON MOSHKEVICH OFFICER |
405 | $168K |
| Nov 2, 2026 | STEVEN L CHAPMAN Officer, Director |
2,866 | $1.2M |
| Nov 2, 2026 | SOLOMON MOSHKEVICH Officer |
3,000 | $1.2M |
| Nov 2, 2026 | DANIEL RABINOWITZ OFFICER |
330 | $137K |
| Nov 2, 2026 | STEVEN CHAPMAN OFFICER, DIRECTOR |
903 | $374K |
| Nov 2, 2026 | MICHAEL BROPHY OFFICER |
313 | $130K |
| Nov 2, 2026 | JONATHAN SHEENA DIRECTOR |
108 | $45K |
| Nov 2, 2026 | MATTHEW RABINOWITZ DIRECTOR |
722 | $299K |
| Oct 30, 2026 | MICHAEL BROPHY Officer |
1,906 | $831K |
| Oct 28, 2026 | JOHN FESKO OFFICER |
917 | $377K |
| Oct 28, 2026 | SOLOMON MOSHKEVICH OFFICER |
1,185 | $487K |
| Oct 28, 2026 | MICHAEL BROPHY Officer |
1,178 | $484K |
| Oct 28, 2026 | DANIEL RABINOWITZ OFFICER |
988 | $406K |
| Oct 28, 2026 | STEVEN CHAPMAN OFFICER, DIRECTOR |
3,499 | $1.4M |
| Oct 28, 2026 | MICHAEL BROPHY OFFICER |
1,222 | $502K |
| Oct 28, 2026 | JONATHAN SHEENA DIRECTOR |
191 | $78K |
| Oct 27, 2026 | JOHN FESKO OFFICER |
771 | $312K |
| Oct 27, 2026 | SOLOMON MOSHKEVICH OFFICER |
997 | $404K |
| Oct 27, 2026 | DANIEL RABINOWITZ OFFICER |
873 | $353K |
| Oct 27, 2026 | JONATHAN SHEENA DIRECTOR |
287 | $116K |
| Oct 27, 2026 | MATTHEW RABINOWITZ DIRECTOR |
1,697 | $687K |
| Oct 27, 2026 | STEVEN CHAPMAN OFFICER, DIRECTOR |
2,236 | $905K |
| Oct 27, 2026 | MICHAEL BROPHY OFFICER |
771 | $312K |
| Oct 21, 2026 | Sheena Jonathan Director |
9,450 | $3.9M |
| Oct 15, 2026 | MATTHEW RABINOWITZ Director, Officer |
50,000 | $19.7M |
| Oct 1, 2026 | STEVEN L CHAPMAN Officer, Director |
1,273 | $526K |
| Oct 1, 2026 | SOLOMON MOSHKEVICH Officer |
3,000 | $1.2M |
| Sep 23, 2026 | Sheena Jonathan Director |
21,064 | $8.2M |
| Sep 15, 2026 | TINKERBELLE II TR U/A DTD 10/22/2021 Officer, Director |
2,000 | $700K |
| Sep 11, 2026 | MATTHEW RABINOWITZ Director, Officer |
200,000 | $65.2M |
| Sep 2, 2026 | SOLOMON MOSHKEVICH OFFICER |
– | – |
| Sep 1, 2026 | STEVEN L CHAPMAN Officer, Director |
1,698 | $545K |
| Sep 1, 2026 | SOLOMON MOSHKEVICH Officer |
3,000 | $962K |
| Aug 7, 2026 | TINKERBELLE II TR U/A DTD 10/22/2021 Officer, Director |
2,000 | $642K |
| Aug 7, 2026 | Sheena Jonathan Director |
18,000 | $6.0M |
| Aug 4, 2026 | MICHAEL BROPHY Officer |
478 | $129K |
| Aug 3, 2026 | JOHN FESKO OFFICER |
292 | $78K |
| Aug 3, 2026 | SOLOMON MOSHKEVICH OFFICER |
405 | $108K |
| Aug 3, 2026 | STEVEN L CHAPMAN Officer, Director |
1,894 | $503K |
| Aug 3, 2026 | SOLOMON MOSHKEVICH Officer |
3,000 | $796K |
| Aug 3, 2026 | DANIEL RABINOWITZ OFFICER |
330 | $88K |
| Aug 3, 2026 | STEVEN CHAPMAN OFFICER, DIRECTOR |
1,167 | $312K |
| Aug 3, 2026 | MICHAEL BROPHY OFFICER |
313 | $84K |
| Aug 3, 2026 | JONATHAN SHEENA OFFICER |
108 | $29K |
| Aug 3, 2026 | MATTHEW RABINOWITZ OFFICER, DIRECTOR |
722 | $193K |
| Jul 29, 2026 | MICHAEL BROPHY Officer |
1,863 | $470K |
| Jul 28, 2026 | JOH N FESKO OFFICER |
917 | $237K |
| Jul 28, 2026 | SOLOMON MOSHKEVICH OFFICER |
1,185 | $306K |
| Jul 28, 2026 | MICHAEL BROPHY Officer |
1,178 | $304K |
| Jul 28, 2026 | DANIEL RABINOWITZ OFFICER |
988 | $255K |
| Jul 28, 2026 | STEVEN CHAPMAN OFFICER, DIRECTOR |
3,525 | $910K |
| Jul 28, 2026 | MICHAEL BROPHY OFFICER |
1,222 | $315K |
| Jul 28, 2026 | JONATHAN SHEENA DIRECTOR |
188 | $49K |
| Jul 27, 2026 | JOHN FESKO OFFICER |
772 | $202K |
| Jul 27, 2026 | SOLOMON MOSHKEVICH OFFICER |
998 | $261K |
| Jul 27, 2026 | DANIEL RABINOWITZ OFFICER |
873 | $229K |
| Jul 27, 2026 | STEVEN CHAPMAN OFFICER, DIRECTOR |
2,163 | $567K |
| Jul 27, 2026 | MICHAEL BROPHY OFFICER |
772 | $202K |
| Jul 27, 2026 | JONATHAN SHEENA DIRECTOR |
285 | $75K |
| Jul 27, 2026 | MATTHEW RABINOWITZ DIRECTOR, OFFICER |
1,697 | $445K |
| Jul 15, 2026 | ROWAN EMMA CHAPMAN Director |
135 | $37K |
| Jul 15, 2026 | Sheena Jonathan Director |
1,500 | $413K |
| Jul 13, 2026 | Sheena Jonathan Director |
9,450 | $2.5M |
| Jul 6, 2026 | TINKERBELLE II TR U/A DTD 10/22/2021 Officer, Director |
1,000 | $280K |
| Jul 1, 2026 | DANIEL RABINOWITZ Officer |
16,800 | $4.6M |
| Jul 1, 2026 | SOLOMON MOSHKEVICH Officer |
3,000 | $819K |
| Jun 24, 2026 | DANIEL RABINOWITZ Officer |
33,600 | $7.9M |
| Jun 24, 2026 | HERMAN ROSENMAN Director |
16,530 | $4.1M |
| Jun 16, 2026 | ROWAN EMMA CHAPMAN Director |
2,964 | $643K |
| Jun 12, 2026 | MATTHEW RABINOWITZ Director, Officer |
100,000 | $21.9M |
| Jun 5, 2026 | GAIL MARCUS Director |
11,000 | $2.4M |
| Jun 4, 2026 | STEVEN L CHAPMAN Officer, Director |
41,124 | $9.1M |
| Jun 1, 2026 | BV369 TRUST Affiliate |
78,000 | $17.2M |
| Jun 1, 2026 | SOLOMON MOSHKEVICH Officer |
3,000 | $655K |
| May 4, 2026 | MICHAEL BROPHY Officer |
482 | $100K |
| May 1, 2026 | SOLOMON MOSHKEVICH Officer |
3,000 | $610K |
| Apr 29, 2026 | MICHAEL BROPHY Officer |
3,070 | $615K |
| Apr 1, 2026 | SOLOMON MOSHKEVICH Officer |
3,000 | $607K |
| Mar 20, 2026 | Sheena Jonathan Director |
6,000 | $1.2M |
| Mar 18, 2026 | Sheena Jonathan Director |
12,441 | $2.5M |
| Mar 13, 2026 | ROWAN EMMA CHAPMAN Director |
122 | $23K |
| Mar 12, 2026 | MATTHEW RABINOWITZ Director, Officer |
200,000 | $39.3M |
| Mar 6, 2026 | DANIEL RABINOWITZ Officer |
16,798 | $3.3M |
| Mar 2, 2026 | STEVEN L CHAPMAN Officer, Director |
3,950 | $790K |
| Mar 2, 2026 | SOLOMON MOSHKEVICH Officer |
3,000 | $600K |
| Feb 3, 2026 | MICHAEL BROPHY Officer |
5,671 | $1.3M |
| Feb 2, 2026 | STEVEN L CHAPMAN Officer, Director |
85,299 | $19.7M |
| Feb 2, 2026 | SOLOMON MOSHKEVICH Officer |
3,000 | $694K |
| Jan 29, 2026 | MICHAEL BROPHY Officer |
1,867 | $440K |
| Jan 28, 2026 | MICHAEL BROPHY Officer |
1,176 | $283K |
| Jan 21, 2026 | MICHAEL BROPHY Officer |
36,573 | $8.6M |
| Jan 2, 2026 | SOLOMON MOSHKEVICH Officer |
2,951 | $676K |
| Jan 2, 2026 | STEVEN L CHAPMAN Officer, Director |
3,848 | $881K |
| Dec 19, 2025 | Sheena Jonathan Director |
4,500 | $990K |
| Dec 17, 2025 | Sheena Jonathan Director |
9,210 | $2.1M |
| Dec 12, 2025 | Herm Rosenman Trust Board member |
48,419 | $11.3M |
| Dec 12, 2025 | SOLOMON MOSHKEVICH Officer |
4,692 | $1.1M |
| Dec 5, 2025 | ROWAN EMMA CHAPMAN Director |
4,366 | $1.1M |
| Dec 1, 2025 | STEVEN L CHAPMAN Officer, Director |
4,400 | $1.0M |
| Dec 1, 2025 | SOLOMON MOSHKEVICH Officer |
3,000 | $714K |
| Nov 24, 2025 | BV369 TRUST Affiliate |
75,000 | $17.7M |
| Nov 20, 2025 | ROY BAYNES Director |
7,668 | $1.7M |
| Nov 20, 2025 | Sheena Jonathan Director |
10,000 | $2.3M |
| Nov 19, 2025 | ROY BAYNES Director |
5,112 | $1.1M |
Show the other 98 notices
From the Form 144 XML filed with the SEC, since Nov 19, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/NTRA/export.csv") into a cell.